Search in biosurfit Start writing...
News
1st October 2024

Biosurfit expands into Contract Development and Manufacturing (CDMO) Services

Biosurfit expands into Contract Development and Manufacturing (CDMO) Services
Back
Azambuja, Portugal, October– biosurfit SA ("biosurfit”), the in-vitro point-of-care (PoC) diagnostics company, announces the launch of a new business division focused on Contract Development and Manufacturing Organization (CDMO) services. Leveraging the company’s state-of-the-art facilities, extensive expertise, and proven track record, this new venture aims to support companies in the development and production of diagnostic and medical devices.

The demand for CDMO services has seen a significant rise in recent years, driven by the increasing need for specialised development, manufacturing capabilities, and the accelerated pace of innovation in the healthcare sector. Companies seeking to bring new products to market often look to services like these to provide essential resources, technical expertise, and manufacturing infrastructure. With the launch of its CDMO business unit, biosurfit is positioning itself as a key partner in this rapidly growing space.

biosurfit has long been recognized for its cutting-edge diagnostic products, the spinit® platform, which delivers rapid and accurate results in point-of-care settings. Now, with the introduction of CDMO services, biosurfit will leverage its deep expertise in several key areas:

  • End-to-End Development: biosurfit offers comprehensive support from concept to finished product. This includes R&D, design, prototype development, validation, and regulatory approvals. The company’s team of scientists and engineers are equipped to handle complex projects, ensuring high-quality outputs at every stage.
  • Microfluidics solutions: Advanced microfluidic development to address diverse sample processing needs with precision and efficiency.
  • Manufacturing Capabilities: designed to handle the production of diagnostic devices, reagents, and consumables. biosurfit’s flexible production capabilities allow for tailored solutions. This adaptability is a key strength in meeting diverse client needs across various project sizes.

biosurfit’s entry into the CDMO market is the beginning of its ambitious plans for growth. The company has already secured partnerships with several industry players to co-develop innovative diagnostic tools that address unmet clinical needs.

João Garcia da Fonseca, founder and Chairman of biosurfit, commented: "Our move into the CDMO business is a strategic extension of our core capabilities in diagnostics. With the infrastructure and knowledge base we’ve built over the years, we are uniquely positioned to help companies accelerate product development and meet regulatory challenges. We are excited to partner with innovators and bring cutting-edge diagnostic solutions to the market faster and more efficiently."

This strategic expansion is a natural extension of biosurfit existing strengths and commitment to innovation. By providing top-tier development and manufacturing services, the company aims to empower other organizations to bring breakthrough diagnostic products to market faster and more efficiently.

With a team that brings together deep scientific knowledge, technical expertise, and a dedication to quality, biosurfit is ready to support the next wave of innovation in healthcare diagnostics. The company’s flexible and responsive approach ensures that it can meet the evolving needs of its clients, making it a trusted partner in the rapidly advancing field of diagnostics.

Rosa Santos, Chief Executive Officer of biosurfit said: "The launch of our CDMO services marks an important milestone in biosurfit growth. We have always prided ourselves on being pioneers in clinical diagnostics, and this new venture allows us to extend our impact even further. By supporting the development and manufacturing needs of other companies, we are not only broadening our business, but also playing a crucial role in advancing healthcare innovation globally."

This business expansion represents an exciting new chapter for the company. biosurfit is ready to make a significant impact in the contract development and manufacturing space. Whether helping clients navigate complex regulatory landscapes, developing new technologies, or scaling production, biosurfit is committed to delivering high-quality, innovative, and clinically relevant diagnostic solutions to its partners, empowering them to make a meaningful impact in the healthcare industry.

For enquiries please contact:

biosurfit | Marketing & Communications
Tel : +351 218 860 169

Failed to load the Page Fonts We apologize, but the user experience may not be the best! Got it